莫西沙星和头孢哌酮钠应用于泌尿生殖系统感染的临床价值分析

目的：对莫西沙星和头孢哌酮钠应用于泌尿生殖系统感染的临床效果进行观察,并从成本和效果综合两方面来探讨两者的临床价值。方法运用随机抽样的方法选择2012年12月—2014年12月在该院进行治疗的泌尿生殖系统感染患者100例,随机将其分为观察组和对照组两组各50例,观察组采用莫西沙星进行治疗,对照组采用头孢哌酮钠进行治疗,比较两组患者的临床疗效,并分析两种治疗方法的成本。结果观察组患者总有效率为94.0%,对照组患者总有效率为92.0%,两组经统计学比较,差异无统计学意义(P>0.05)；观察组C/E为11.38,对照组为25.59。结论莫西沙星与头孢哌酮治疗泌尿生殖系统感染的临床疗效相当,不过从成本-效果来比较莫西沙星更具有优势,是一种方便、经济、有效的治疗方案。

Analysis of Clinical Value of Moxifloxacin and Cefoperazone Sodium in the Urinary System Infection

Objective To observe the clinical effect of moxifloxacin and cefoperazone sodium in the urinary system infection and discuss the clinical value from the two aspects of cost and effect. Methods 100 cases of patients with urinary system in-fection treated in our hospital from December 2012 to December 2014 were randomly selected and randomly divided into two groups with 50 cases in each, the observation group were treated with moxifloxacin, the control group were treated with cefoperazone sodium, and the clinical curative effects of the two groups were compared, and the costs of the two treatment methods were analyzed. Results The difference in the total effective rate between the observation group and the control group was not statistically obvious, (94.0%vs 92.0%), P>0.05, and the C/E was 11.38 in the observation group and 25.59 in the control group. Conclusion The clinical curative effects of moxifloxacin and cefoperazone sodium in the urinary system infection are similar, but the moxifloxacin is more advantageous in terms of cost-effect, and it is a convenient, economic and effective treatment program.